LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Longeveron Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.39+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $43.61M
- P/E (TTM)
- –
- Dividend yield
- –
Longeveron Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical trial revenue | $1.06M | $1.07M | $954.00K | $1.04M | $1.16M | $1.15M | $1.40M | $1.08M | $1.02M | $945.00K | $668.00K | 89.5% | -8.2% |
| Contract manufacturing revenue | $114.00K | $126.00K | $222.00K | $252.00K | $592.00K | $602.00K | $487.00K | – | – | – | – | 9.6% | -80.7% |
| National Institute of Health - grant [Member] | – | – | – | – | – | – | – | – | – | – | $41.00K | – | – |
| Grant revenue | – | – | – | – | – | – | – | – | – | – | $41.00K | – | – |
| National Institutes of Health Grant [Member] | – | – | – | – | – | – | – | – | – | – | $41.00K | – | – |
| Contract manufacturing lease revenue | – | – | $23.00K | $144.00K | $324.00K | $477.00K | $503.00K | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Longeveron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.